Prosecution Insights
Last updated: November 20, 2026
Application No. 19/190,286

METHODS AND DEVICES FOR INCREASING AQUEOUS DRAINAGE OF THE EYE

Non-Final OA §102§103
Filed
Apr 25, 2025
Priority
Sep 10, 2021 — provisional 63/242,856 +3 more
Examiner
SHI, KATHERINE MENGLIN
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Iantrek Inc.
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
1y 5m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
706 granted / 902 resolved
+8.3% vs TC avg
Strong +22% interview lift
Without
With
+22.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
37 currently pending
Career history
938
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
40.1%
+0.1% vs TC avg
§102
22.3%
-17.7% vs TC avg
§112
25.8%
-14.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 902 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment In response to the preliminary amendment filed on 1/16/2026, claims 1-25 and newly added claims 26-34 are pending. Effective Filing Date The instant application, filed 4/25/2025, is a continuation of 17/941,307, filed 9/9/2022, which claims priority to U.S. Provisional Application 63/344,443, filed 5/20/2022; U.S. Provisional Application 63/254,436, filed 10/11/2021; and U.S. Provisional Application 63/242,856, filed 9/10/2021. Claims 1-34 are directed to subject matter that was introduced for the first time in U.S. Provisional Application 63/344,443, filed 5/20/2022 and the parent application, filed 9/9/2022. The earlier U.S. Provisional Applications (63/254,436 and 63/242,856) do not provide support for the tissue disruptor has a maximum thickness between the radially inner surface and the radially outer surface of the elongate, flexible shaft; dilating Schelmm’s Canal with the tissue disruptor to improve aqueous outflow, and the micro-interventional tool comprising a laser-shaped flat sheet of super-elastic memory-shape material having a distal region comprising an elongate, flexible shaft with a non-circular cross-section and a tissue disrupting profile. The features regarding the tissue disruptor having a maximum thickness between the radially inner surface and the radially outer surface of the elongate, flexible shaft and the micro-interventional tool comprising a laser-shaped flat sheet of super-elastic memory-shape material having a distal region comprising an elongate, flexible shaft with a non-circular cross-section and a tissue disrupting profile are not described and supported until the filing of U.S. Provisional Application 63/344,443, filed 5/20/2022. The feature regarding dilating Schelmm’s Canal with the tissue disruptor to improve aqueous outflow is not described until the filing of parent application 17/941,307, filed 9/9/2022. Therefore, the effective filing date for the subject matter of is claims 1-25 is 5/20/2022 and the effective filing date of claims 26-34 is 9/9/2022. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-3, 7, 8, 22-25 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ianchulev (US 2021/0022920). Ianchulev discloses the following limitations: Claim 1. A method of improving aqueous drainage of an eye ([0005]), the method comprising: introducing a distal portion of a tissue disruption device (2C) into an anterior chamber of an eye through an ab interno insertion location towards an anterior angle of the eye ([0069], [0117]; Fig. 22A), the distal portion comprising: an elongate, flexible shaft (6C) of super-elastic memory-shape material (0073], [0092]) comprising a radially inner surface (bottom surface) that is connected to a radially outer surface (top surface) by two lateral sides (left side, right side) (Figs. 13, 14); a distal-most end (15C) ([0093]); and a tissue disruptor (10C) proximal of the distal-most end formed on the radially outer surface (Fig. 13), wherein the tissue disruptor has a maximum thickness ([0092]; i.e. height) between the radially inner surface and the radially outer surface (the tissue disruptor 10C is considered a part of the shaft since it is disclosed as being formed with the shaft. Therefore, surfaces of the tissue disruptor 10C, much like Applicant’s invention, is considered a continuing surface of the shaft and therefore the maximum thickness of the tissue disruptor is considered between the radially inner surface and the radially outer surface of the shaft); positioning the tissue disruptor against a wall of the anterior angle of the eye outside of Schlemm's canal ([0072], [0073]); and moving the tissue disruptor relative to the wall to reduce a thickness of the wall with the tissue disruptor ([0074], [0112], [0124]; i.e. removal of tissue results in reducing a thickness of the wall). Claim 2. The method of claim 1, wherein the wall comprises a scleral wall ([0073]). Claim 3. The method of claim 2, wherein the thickness of the wall is reduced by partial thickness cutting, debriding, abrading, shaving, or ablating the wall with the tissue disruptor ([0074], [0112], [0124]). Claim 7. The method of claim 1, wherein the maximum thickness (i.e. height) of the tissue disruptor is at least 150 microns up to about 2 mm ([0092]; i.e. height is between 150 50 800 microns). Claim 8. The method of claim 1, wherein the shaft has a cross-sectional shape taken transverse to a length of the shaft between that is non-circular (Fig. 14; [0094]). Claim 22. The method of claim 1, wherein introducing the distal portion further comprises introducing an introducer tube (17) projecting from a distal end region of a proximal housing (13), wherein at least a portion of the shaft extends through a lumen of the introducer tube ([0072]; Figs. 1-3). Claim 23. The method of claim 22, wherein the shaft is configured to be advanced from the introducer tube and retracted into the introducer tube ([0026], [0075]). Claim 24. The method of claim 23, wherein the shaft develops a spring-load as the shaft extends from the introducer tube ([0007], [0025], [0073], [0094]). Claim 25. The method of claim 23, further comprising applying a radially outward force with the shaft as the shaft extends from the introducer tube ([0025], [0026], [0073]). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 9 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ianchulev. Claim 9. Ianchulev discloses the invention substantially as claimed above, including the cross-sectional shape is non-circular ([0094]) but fails to disclose the cross-sectional shape is square or rectangular. However, before the effective filing date of the invention, it would have been an obvious matter of design choice to a person of ordinary skill in the art to modify the non-circular shape of Ianchulev et al to be specifically square or rectangular because Applicant has not disclosed that these two shapes provides an advantage, is used for a particular purpose or solves a stated problem. In paragraphs [0093], [0112], [0127] of the published instant specification, Applicant discloses the shape may be non-circular “such as square or rectangular”. Applicant explicitly discloses the cross-sectional shape may be “circular or non-circular” and may be elliptical ([0112]). The elliptical configuration is akin to the non-circular cross-sectional shape of Ianchulev having a major axis (53) and minor axis (51). However, Applicant has not provided evidence, such as how the claimed square and rectangular cross-sectional shapes have unexpected results over the prior art in the claimed method. One of ordinary skill in the art, furthermore, would have expected Applicant’s invention to perform equally well with the non-circular shape of Ianchulev because the shaft of Ianchulev is designed to be inserted into the same anatomical region and to perform the same procedure. Therefore, it would have been prima facie obvious to one skilled in the art to modify the non-circular shape of Ianchulev to square or rectangular since this is a mere obvious design choice that fails to patentably distinguish the invention of claim 9 from Ianchulev. Claim(s) 17 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ianchulev in view of Tu et al (US 2002/0169130). Claim 17. Ianchulev discloses the invention substantially as claimed above, including an incision being made (Fig. 22A) but fails to disclose the ab interno insertion location is a corneal incision having a size less than about 2.75 mm. However, in the same field of endeavor for treating glaucoma, Tu et al teaches an ab interno insertion ([0072]), wherein a corneal incision is made having a size of less than about 1 mm ([0118]). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the invention to modify the method of Ianchulev to include the ab interno insertion location to be a corneal incision having a sizes less than 1 mm (within the claimed range) as taught by Tu et al since such an incision is self-sealing ([0118]). Claim(s) 18 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ianchulev in view of Smedley et al (US 2007/0118147). Claim 18. Ianchulev discloses the invention substantially as claimed above, but fails to disclose the step of further performing phacoemulsification of a cataract. However, in the same field of endeavor for treating glaucoma, Smedley et al teaches performing phacoemulsification of a cataract ([0009], [0131]). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the invention to modify the method of Ianchulev to include the step of performing phacoemulsification of a cataract to remove damaged or diseased natural lens tissue as a result of the fluid pressure in glaucoma disease. Allowable Subject Matter Claims 27-34 are allowed. Claims 4-6, 10-16, 19-21 and 26 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: the closest prior art of record, Ianchulev, discloses the invention substantially as claimed above. In regard to claim 4, the prior art of record does not disclose or fairly suggest either singly or in combination the claimed method comprising, wherein moving the tissue disruptor comprises retracting the tissue disruptor relative to the insertion location. Instead, the retraction movement in Ianchulev is only to adjust the stiffness of the shaft ([0026], [0075]). The removal of tissue in Ianchulev is directed to forward movement ([0118]). In regard to claim 10, the prior art of record does not disclose or fairly suggest either singly or in combination the claimed method comprising modifying a second wall of the anterior angle of the eye using a second tissue disruptor. In regard to claim 19, the prior art of record does not disclose or fairly suggest either singly or in combination the claimed method comprising, the tissue disruptor has a distal face and a proximal face, the distal face sloping from a first thickness of the shaft distal to the tissue disruptor towards the maximum thickness and the proximal face tapering down from the maximum thickness to a second thickness of the shaft proximal to the tissue disruptor, wherein the first thickness, the maximum thickness, and the second thickness are each between the inner and outer surfaces, and wherein the distal face of the tissue disruptor is a blunt tissue-engaging surface without any cutting element. In regard to claim 26, the prior art of record does not disclose or fairly suggest either singly or in combination the claimed method comprising dilating Schlemm's canal with the second tissue disruptor. In regard to claims 27 and 32, the prior art of record does not disclose or fairly suggest either singly or in combination the claimed method comprising: dilating Schlemm's Canal with the tissue disruptor to improve aqueous outflow. The current state of the art involving dilation of Schelmm’s Canal instead uses other elements to perform dilation. Prior arts such as Badawi et al (US 2013/0253438) uses an injection of viscoelastic fluid to perform the dilation and Lynch (WO 0064389) uses an inflatable dilator to perform dilation. Therefore, in view of the prior art and its deficiencies, Applicant’s invention is rendered novel and non-obvious, and thus, is allowable as claimed. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KATHERINE M SHI whose telephone number is (571)270-5620. The examiner can normally be reached Mon-Thurs, 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Darwin Erezo can be reached at (571)272-4695. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KATHERINE M SHI/Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Apr 25, 2025
Application Filed
Jan 16, 2026
Response after Non-Final Action
Oct 02, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797060
CORTICAL BUTTON FOR SURGICAL FIXATION AND A SURGICAL FIXATION DEVICE THEREOF
3y 0m to grant Granted Nov 17, 2026
Patent 12797588
BALLOON CATHETER
2y 9m to grant Granted Nov 17, 2026
Patent 12797073
Sutureless Connector System for Intravascular Device Access
1y 9m to grant Granted Nov 17, 2026
Patent 12788561
VALVE LEAFLET TREATMENT SYSTEMS AND METHODS
3y 6m to grant Granted Nov 10, 2026
Patent 12778736
SYSTEMS, METHODS AND DEVICES FOR EMBOLIC PROTECTION
3y 11m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
99%
With Interview (+22.0%)
3y 0m (~1y 5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 902 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month